Share:
Interim Analysis of Second Confirmatory Phase 3 Study in Fibromyalgia
Expected in Third Quarter 2021
Deep Pipeline Progressing with Three Central Nervous System
(CNS) Programs Expected to Enter Phase 2 Trials This Year
At March 31, 2021, Cash and Cash Equivalents Totaled Approximately $164 Million
CHATHAM, N.J., May 10, 2021 (GLOBE NEWSWIRE) Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced financial results for the first quarter ended March 31, 2021 and provided an overview of recent operational highlights. Tonix possesses a deep pipeline of high-value programs ranging from preclinical to mid-Phase 3 development, with three CNS programs poised to enter Phase 2 trials this year, said Seth Lederman, M.D., President and Chief Executive Officer. Our strategy is to in-license, acquire or internally invent high impact therapeutic programs which we can validate, de-risk and advance